T-cell differentiation and effector functions are shaped by the integration of different signals from the environment. The process initiated when the T-cell receptor is engaged is then modulated by activating (costimulatory molecules and cytokines) and inhibitory (checkpoint receptors and cytokines) signals, which have a direct impact on the development or function of effector and/or regulatory T (Treg) cells ([@B1], [@B2]). In pre-clinical human or animal studies, the manipulation of T-cell function has been attempted via numerous different approaches, including (i) manipulation of metabolism ([@B3]), (ii) modulation of autophagy, (iii) regulation of epigenetic processes ([@B4]), (iv) agonistic or antagonistic therapies engaging cellular receptors ([@B5]), (v) the use of cytokines/chemokines to skew immune response profiles, (vi) the expansion/depletion of certain cell type (i.e., depletion of Tregs or expansion of effector T cells specific for a certain pathogen) ([@B6]), and (vii) the use of diverse immunomodulating natural or synthetic compounds that could regulate any of the above mentioned aspects of the immune response ([@B7]), among others. The goal of the current Research Topic is to highlight some of these approaches and to focus on the diverse ways of modulating T-cell function or frequency in health and disease.

Within this eBook, some authors addressed the potential of diverse strategies, such as manipulating metabolic pathways, autophagy processes, and/or modification of the redox cellular milieu with an impact on T-cell function. [Cluxton et al.](https://doi.org/10.3389/fimmu.2019.00115) proposed that the fundamental difference in metabolic requirements of human Tregs and Th17 cells could be used in order to modulate inflammatory responses in human diseases. Similarly, [Liang et al.](https://doi.org/10.3389/fimmu.2018.02584) work focused on the effect of sulforaphane (SFN), a compound derived from certain vegetables, as a modulator of the extracellular redox milieu. They observed that SFN induced a pro-oxidative state, consequently inhibiting Th17-related cytokines via targeting of STAT3. They finally stated that SFN could be a novel option for treatment of inflammatory/autoimmune diseases, such as rheumatoid arthritis. Continuing with the importance of metabolism in mediating T-cell function, [Nicoli et al.](https://doi.org/10.3389/fimmu.2018.02372) suggested in their review that antigen-presenting cells could be metabolically manipulated through TLR4, TLR9, or STING to induce metabolic and/or autophagy changes in order to subsequently impact on CD8+ T cell responses, while [Merkley et al.](https://doi.org/10.3389/fimmu.2018.02914) revisited the influence of autophagy over T-cell responses by modulating several aspects of antigen-presenting cells\' function and the impact of this modulation over T-cell signaling, survival, cytokine production, and metabolism.

The impact of post-transcriptional modifications on T-cell responses was explored in a very nice study by [Hao et al.](https://doi.org/10.3389/fimmu.2018.02089). They unraveled, in a rat model of autoimmune hepatitis, the major role of glycosylation on Treg differentiation and the impact of this deficiency on disease development. They demonstrated that deficiency in O-GlcNAc glycosylation affects the Notch function, a signaling pathway previously reported to promote the differentiation and survival of Tregs. As a result, impaired Treg differentiation allowed for increasing CD4+ T cell infiltration in the liver, indicating that modulation of O-GlcNAc glycosylation in this model could be a target for immunotherapy. In a related disease model, [Kroger et al.](https://doi.org/10.3389/fimmu.2018.01891) enumerated the various immunotherapies aimed at controlling autoimmunity in type I diabetes, including among other modulation of regulatory T cells and cytokines.

A more traditional approach used by several authors within this eBook consists of underscoring how signaling through various receptors modifies cellular functions in T cells. For instance, [Holgado et al.](https://doi.org/10.3389/fimmu.2018.02814) have described for the first time the role of CD32, a low-affinity Fc-gamma receptor, as promoter of human CD4+ T-cell responses that consequently increases cell proliferation and creates a wide pattern of cytokines triggered by polyclonal stimulation, thus enhancing inflammatory responses. Additionally, the work of [Jogdand et al.](https://doi.org/10.3389/fimmu.2018.01041) explored the relevance of ICOS signaling in the context of the blood stage of *Plasmodium berghei* ANKA infection. In this setting, they observed that depletion of ICOS+ cells from infected mice induced longer survival and lower parasitemia. Also, they observed that ICOS+ T cells also expressed IFN-γ and the transcription factor Tbet; both positively correlated with ICOS expression, therefore suggesting a positive regulation loop between ICOS expression and T-cell function. [Abderrazak et al.](https://doi.org/10.3389/fimmu.2018.02269) observed in their manuscript that VLA-2 integrin signaling protected T cells from methotrexate-induced apoptosis (a drug used for rheumatoid arthritis treatment), and "rescued" cells producing IL-17 and IFN-γ contributing to the perpetuation of inflammation and the development of methotrexate resistance seen in rheumatoid arthritis. Finally, [Tosello Boari et al.](https://doi.org/10.3389/fimmu.2018.02347) demonstrated the importance of IL-17 cytokines and their receptor IL-17RA in a model of chronic infection with *Trypanosoma cruzi*. In their work, the authors demonstrated that signaling through IL-17RA is required for the maintenance of effector function in CD8+ T cells in a cell-intrinsic manner. In fact, deficiency in IL-17RA rendered CD8+ T cells more dysfunctional, and blockade of PD-L1, a checkpoint inhibitor currently targeted in many cancer models, partially restored the effector function of these cells. In line with this topic, [Panagioti et al.](https://doi.org/10.3389/fimmu.2018.00276) discussed in their review article the various T-cell inducing vaccines used in protection against chronic infections, particularly in viral infections.

Chemokines and/or cytokines themselves could serve as therapeutic targets. In their work, [Ushio et al.](https://doi.org/10.3389/fimmu.2018.02594) used a murine model for Sjögren\'s syndrome as a way to understand the role of CCL22 in this autoimmune disease. They observed that CCL22-producing tissue-resident macrophages may control autoimmune lesions by enhancing the migratory capacity of CD4+ T cells to the affected tissue as well as by inducing IFN-γ production of T cells. Another example of how cytokines and their downstream effects could be used as targets for immunotherapy is addressed in the work of [Min et al.](https://doi.org/10.3389/fimmu.2018.02022). The authors clearly showed the relevance of the Type I IFN/IL-10 axis in the induction of antigen-specific T-cell function and the generation of T-cell memory in a mouse model for scrub typhus, an infectious disease caused by the intracellular bacteria *Orientia tsutsugamushi*. Their work contributes to a better understanding of the mechanisms behind the short longevity of antigen-specific adaptive immunity observed during this human infection ([@B8]).

A different approach proposed by some authors consists of expanding effector cells or limiting the function of regulatory cells with the aim to improve immune responses against pathogens. [Salido et al.](https://doi.org/10.3389/fimmu.2018.02443) expanded *in vitro* CD8+ T cells from HIV+ subjects on combination antiretroviral therapy (cART). Their ultimate goal was to explore new strategies aimed at modulating CD8+ T lymphocytes to achieve functional cure of HIV infections. They observed that expanded cells were polyfunctional, skewed toward an effector phenotype, and that PD-1 expression was clustered in HIV-specific effector memory CD8+ T cells, which had the highest cytokine-producing capacity. Antiviral activity was also enhanced in these cells, indicating that, despite being dampened in subjects on cART, the HIV-specific CD8+ T-cell response could be selectively stimulated and expanded *in vitro*. On the other hand, the work of [Araujo Furlan et al.](https://doi.org/10.3389/fimmu.2018.02555) explored the role of Tregs during *Trypanosoma cruzi* infection and the impact of Treg frequency over pathology. They observed that massive accumulation of effector immune cells resulted in a diminished frequency of Tregs and inversely correlated with the magnitude of the immune response as well as with emergence of acute immunopathology. After transfer of Tregs, CD8+ T-cell function was affected and parasite control in blood and tissues was diminished, highlighting the relevance of Tregs over cytotoxic immunity against the parasite. Another important population of T cells that was reviewed by [Shiromizu et al.](https://doi.org/10.3389/fimmu.2018.02389) consists of γδ T cells, whose role during autoimmunity and infection has been analyzed in depth in their work. They have also revised concepts about the mechanisms that modulate γδ T-cell function, giving the framework to consider the modulation of these cells as a tool to control pathological immune responses.

Collectively, the wide spectrum of original papers and reviews presented in this eBook have provided a comprehensive overview of potential strategies aiming to convert a pathological immune response into a protective one through the control or reprogramming of specific T-cell subsets. The insights outlined here will hopefully help shape future therapeutics for the treatment of infectious and autoimmune diseases.
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